Stockscreener 앱 받기
29.52
2.09%
-0.535
전일 마감가:
$30.05
열려 있는:
$30.24
하루 거래량:
1.62M
Relative Volume:
0.66
시가총액:
$3.73B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-14.54
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
+4.55%
1개월 성능:
+29.90%
6개월 성능:
+61.57%
1년 성능:
+7.34%
1일 변동 폭
$29.39
$30.44
1주일 범위
$28.05
$30.48
52주 변동 폭
$16.10
$35.72
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
29.52 | 3.80B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.04 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.82 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.88 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
823.87 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.48 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Earnings To Watch: Apellis Pharmaceuticals Inc (APLS) Reports Q3 2025 Result - GuruFocus
Apellis Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Published on: 2025-10-29 02:11:34 - newser.com
How moving averages guide Apellis Pharmaceuticals Inc. tradingJuly 2025 Pullbacks & Capital Protection Trading Alerts - newser.com
Why retail investors favor Apellis Pharmaceuticals Inc. stockJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - Fundação Cultural do Pará
Apellis Pharmaceuticals Inc. stock prediction for this weekQuarterly Profit Summary & Long-Term Capital Growth Ideas - newser.com
Will a bounce in Apellis Pharmaceuticals Inc. offer an exitWeekly Gains Summary & Safe Entry Point Identification - newser.com
Is Apellis Pharmaceuticals Inc. stock attractive for income investorsEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recoveryLong Setup & Detailed Earnings Play Alerts - newser.com
Regression analysis insights on Apellis Pharmaceuticals Inc. performancePortfolio Return Report & Entry and Exit Point Strategies - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueQuarterly Performance Summary & Technical Entry and Exit Tips - newser.com
What valuation ratios show for Apellis Pharmaceuticals Inc. (1JK) stockMarket Performance Recap & Advanced Technical Signal Analysis - newser.com
Will Apellis Pharmaceuticals Inc. (1JK) stock rise with strong economyWeekly Gains Report & AI Powered Market Trend Analysis - newser.com
Will Apellis Pharmaceuticals Inc. stock maintain dividend yieldJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Real time scanner hits for Apellis Pharmaceuticals Inc. explainedWeekly Trade Report & High Yield Equity Trading Tips - newser.com
What high frequency data says about Apellis Pharmaceuticals Inc.Market Risk Analysis & Consistent Return Strategy Ideas - newser.com
Can Apellis Pharmaceuticals Inc. (1JK) stock survive global slowdownQuarterly Trade Summary & Verified Entry Point Signals - newser.com
How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.Quarterly Profit Review & Step-by-Step Trade Execution Guides - newser.com
Can Apellis Pharmaceuticals Inc. stock sustain market leadership2025 Market Outlook & Weekly Breakout Watchlists - Fundação Cultural do Pará
How Apellis Pharmaceuticals Inc. stock performs in weak economyMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Will Apellis Pharmaceuticals Inc. stock gain from lower inflation2025 Price Targets & Reliable Breakout Stock Forecasts - newser.com
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아펠리스 주식 (APLS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Timothy Eugene | Chief Financial Officer |
Oct 21 '25 |
Sale |
28.03 |
10,000 |
280,300 |
110,936 |
0.12%
2.47%
자본화:
|
볼륨(24시간):